WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013147711) BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/147711 International Application No.: PCT/SG2013/000126
Publication Date: 03.10.2013 International Filing Date: 01.04.2013
Chapter 2 Demand Filed: 30.01.2014
IPC:
C07D 487/04 (2006.01) ,C07D 265/06 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/5025 (2006.01) ,A61P 35/00 (2006.01) ,A61P 3/10 (2006.01)
Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH[SG/SG]; 1 Fusionopolis Way, #20-10 Connexis Singapore 138632, SG
Inventors: NACRO, Kassoum; SG
DURAISWAMY, Athisayamani, Jeyaraj; SG
CHENNAMANENI, Lohitha, Rao; SG
Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office Singapore 903031, SG
Priority Data:
1205669.330.03.2012GB
Title (EN) BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
(FR) DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES À TITRE DE MODULATEURS DE MNK1 ET MNK2 ET LEURS UTILISATIONS
Abstract:
(EN) The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
(FR) Cette invention concerne certains composés (par ex., composés d'imidazo- pyrazine, d'imidazopyridine, d'imidazopyridazine et d'imidazopyrimidine) qui agissent comme des inhibiteurs des kinases MNK2a, MNK2b, MNK1a, et MNK1b qui interagissent avec les MAP kinases. Cette invention concerne en outre des compositions pharmaceutiques les contenant, et l'utilisation de ces composés dans la préparation d'un médicament destiné à prévenir et à traiter des maladies (par ex., maladies prolifératives (par ex., cancer), maladies inflammatoires, maladie d'Alzheimer), ainsi que des méthodes pour traiter ces maladies.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)